RSS | Login | Register

REMERON

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare REMERON to:

Generic Name for REMERON

Mirtazapine 15mg+, 30mg+, 45mg, tabs; +scored.

Legal Classification:

Pharmacological Class for REMERON

Tetracyclic.

Manufacturer of REMERON

Merck & Co., Inc.

Indications for REMERON

Depression.

Adult dose for REMERON

Initially 15mg once daily at bedtime; increase at intervals of at least 1–2 weeks. Usual range: 15–45mg daily. SolTab: Dissolve on tongue and swallow with or without water.

Children's dosing for REMERON

Not recommended.

Also:

REMERON SOLTAB

Contraindications for REMERON

During or within 14 days of MAOIs.

Warnings/Precautions for REMERON

Hepatic or moderate to severe renal dysfunction. Diseases that affect metabolism or hemodynamic response. History of mania/hypomania. Seizure disorders. Suicidal ideation. History of MI. Angina. Ischemic stroke. Hypovolemia. Elderly. Pregnancy (Cat.C). Nursing mothers.

Interactions for REMERON

See Contraindications. Possible serious/fatal reactions with MAOIs. Potentiation with alcohol, diazepam, other CNS depressants. Caution with drugs metabolized by and/or that inhibit CYP450.

Adverse Reactions for REMERON

Somnolence, increased appetite, weight gain, dizziness, nausea, dry mouth, constipation, asthenia, flu syndrome, edema, CNS effects; hypo- or hypertension, elevated cholesterol, triglycerides, or transaminases; agranulocytosis (rare).

How is REMERON supplied?

Tabs 15mg, 30mg—30, 100
45mg—30
SolTabs—30

Related Disease:

Depression

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oleptro available for major depressive disorder

August 10, 2010

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Phase 3 study of TC-5214 for major depressive disorder (MDD)

June 23, 2010

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

NDA submitted for vilazodone for major depressive disorder (MDD)

March 23, 2010

Clinical Data Inc. announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of vilazodone for the treatment of major depressive disorder (MDD).